Rationale, design, and experiences from the vanguard phase of the bariatric surgery for the reduction of cardiovascular events (BRAVE) trial - 08/09/26
, David Conen, MD, MPH a, b, Aristithes Doumouras, MD, MPH b, c, Emma Van Reekum, MD a, b, Shrikant I. Bangdiwala, PhD a, b, Kumar Balasubramanian, PhD a, Shaheena Bashir, PhD a, Sumathy Rangarajan, BSc, MSc a, Marie-Eve Piché, MD, PhD d, Myriam Pettigrew, MSc d, Dawn Agapay, CCRA a, Aldo P. Maggioni, MD e, Stefan Störk, MD, PhD f, Denis Pajecki, MD, PhD g, Ryan A. Davey, MD h, Remi Kouz, MDCM, MSc i, Roselyne Villiard, MD, MSc j, Satya Dash, MD, PhD k, Alvaro Avezum, MD l, Ricardo Cohen, MD, PhD m, Olga Castaner, MD, PhD n, Paul Poirier, MD, PhD d, Mehran Anvari, MBBS, PhD b, c, Salim Yusuf, MBBS, DPhil a, bABSTRACT |
Background |
Observational studies suggest that metabolic/bariatric surgery (MBS) reduces mortality and major adverse cardiovascular events in patients with obesity, but adequately powered randomized trials (RCTs) are lacking. The Bariatric Surgery for the Reduction of Cardiovascular Events (BRAVE) trial was designed to address this evidence gap.
Methods |
BRAVE is an investigator-initiated, multi-center, open-label RCT with blinded endpoint adjudication comparing MBS vs guideline-based medical weight management (MWM) in adults with obesity and high-risk cardiovascular disease (CVD). Eligible participants have a body-mass index ≥35 kg/m² or ≥30 kg/m² with type 2 diabetes or age >55 years, and prior myocardial infarction (MI), coronary intervention, heart failure (HF), atrial fibrillation (AF) with elevated CHA₂DS₂-VASc score, cerebrovascular disease, or peripheral arterial disease. Participants are randomized 1:1 to MBS (sleeve gastrectomy, Roux-en-Y gastric bypass, or duodenal switch) or MWM, which includes dietary, behavioral, and pharmacologic therapies. The primary outcome is the composite of all-cause death, MI, stroke, HF events, coronary revascularization, AF hospitalization, and renal events. A vanguard phase of 200 participants was implemented to optimize recruitment and logistics.
Results |
As of October 2025, 2,514 individuals have been screened from 17 centers in Canada, Brazil, Italy and Spain, with 444 entered MBS work-up, and 200 have been randomized. The randomized cohort (mean age 59.8 years; 37% female; mean BMI 44.0 kg m⁻²) has high burden of hypertension (82%), diabetes (45%), coronary artery disease (44%), HF (39%), and AF (48%). Recruitment barriers were identified and addressed through targeted education and enhanced patient engagement.
Conclusions |
BRAVE is the first large RCT evaluating whether MBS safely reduces major cardiovascular events compared with medical therapy in high-risk patients with obesity.
Trial Registration |
ClinicalTrials.gov Identifier: NCT05531474.
Le texte complet de cet article est disponible en PDF.Plan
Vol 302
Article 107544- décembre 2026 Retour au numéro
Article précédent
- Table of Contents
- Intensive blood-pressure control for the prevention of major cardiovascular events in patients with type 2 diabetes: Rationale, design and baseline characteristics of the OPTIMAL-DIABETES randomized trial
- Karla Santo, Eduardo Martins, Gisele S. Silva, Patricia O. Guimarães, Caio A.M. Tavares, João Brainer, Frederico Monfardini, Josué Nieri, Silvia R.L. Assis, João S. Felício, Fábio S. Silveira, Audes D.M. Feitosa, Miguel N. Hissa, Dario C. Sobral-Filho, José F. Vilela-Martin, Elizabeth E.S. Cestario, Juan C. Yugar-Toledo, Marcelo C. Batista, Luiz Turatti, Andrea A. Brandão, Weimar S. Barroso, Andrei C. Sposito, Luciano F. Drager, Luiz A. Bortolotto, Sandra C. Fuchs, Marcelo Franken, Pedro A. Lemos, Raul D. Santos, Anthony Rodgers, Paul K. Whelton, Flavio D. Fuchs, Otavio Berwanger
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?